Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
AssigneeImbria Pharmaceuticals, Inc.
InventorsNeil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
Life of this patent
Estimating the term…
Abstract
The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
Claims22
A crystal comprising a Form A polymorph of a monohydrate hydrochloride salt of a compound of Formula (X):
- wherein the Form A polymorph has an XRPD pattern as shown in FIG. 4.
A pharmaceutical composition comprising a crystal comprising a Form A polymorph of a monohydrate hydrochloride salt of a compound of Formula (X):
- wherein the Form A polymorph has an XRPD pattern as shown in FIG. 4.
A method of treating a condition in a subject, the method comprising providing to a subject having, or at risk of developing, a condition a composition comprising a therapeutically effective amount of a Form A polymorph of a monohydrate hydrochloride salt of a compound of Formula (X):
- wherein the Form A polymorph has an XRPD pattern as shown in FIG. 4, and wherein the condition is selected from the group consisting of aneurysm, angina, atherosclerosis, cardiomyopathy, cerebral vascular disease, congenital heart disease, coronary artery disease, coronary heart disease, diabetic cardiomyopathy, heart attack, heart disease, heart failure, hypertension, ischemic heart disease, pericardial disease, peripheral arterial disease, rheumatic heart disease, stroke, transient ischemic attacks, and valvular heart disease.
Dependencies are inferred from the claim text.